In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni raise $5M in a Seed funding round, initial clinical studies, appoint new executives, enter new strategic partnerships, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Successfully completed enrollment for its CAPTURE-HF study. The two-phase data acquisition study aims to assess the accuracy, safety, and usability of Acoria’s SAVE Sensor System, a non-invasive cardiac and pulmonary sensing device.
Announced the launch of its EMBO-02 clinical study of NeoCast™ to treat chronic subdural hematomas. NeoCast is an injectable, shear-responsive, non-adhesive, solvent-free, liquid embolic material designed for deep distal penetration.
Appointed Nancy Briefs as its new Chair of the Board. Echopoint Medical is developing a series of optical sensors that integrate into microcatheters to enhance guidance and improve outcomes for interventional cardiology procedures.
Announced a partnership with Medoxa. Through this partnership, the companies aim to address the rising need for endoscopic ultrasound in the Europe, Middle East, and Africa (EMEA) region, where the procedure has remained underutilized.
Announced that its cross-modal imaging technology was published in Scientific Reports. The platform technology combines novel multiphoton laser scanning with reflectance confocal microscopy to provide real-time, actionable cellular information.
Achieved two clinical milestones for its GammaTileⓇ. GammaTile was implanted in its 1,500th patient and the GammaTile multi-center Registry (NCT04427384) enrolled its 400th patient to further demonstrate the device's efficacy and safety.
Raised $5M in an oversubscribed Seed funding round led by Dexcom Ventures. The funds will be used to advance the development of its fenoTRACK device, a portable, non-invasive breath test to measure airway inflammation via fractional exhaled nitric oxide.
Appointed Ron Andrews as its Strategic Consultant to the CEO. OncoHost develops PROphetⓇ, a plasma-based proteomic pattern analysis tool that, in its initial application for non-small cell lung cancer (NSCLC), uses a single blood sample to guide first-line immunotherapy decision-making.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
.png)
